Tongue Squamous Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Aliases & Classifications for Tongue Squamous Cell Carcinoma

MalaCards integrated aliases for Tongue Squamous Cell Carcinoma:

Name: Tongue Squamous Cell Carcinoma ¹¹ ¹⁴ ¹⁶

Squamous Cell Carcinoma of Tongue ⁷¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Oral diseases Gastrointestinal diseases Smell/Taste diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0050865

NCIt ⁴⁹ C4648

SNOMED-CT ⁶⁸ 276952000

EFO ¹⁶ EFO_1000055

UMLS ⁷¹ C0349566

Sources

Summaries for Tongue Squamous Cell Carcinoma

Disease Ontology: ¹¹ A head and neck squamous cell carcinoma that is located in the tongue.

MalaCards based summary: Tongue Squamous Cell Carcinoma, also known as squamous cell carcinoma of tongue, is related to tongue carcinoma and oral squamous cell carcinoma. An important gene associated with Tongue Squamous Cell Carcinoma is MIR222 (MicroRNA 222), and among its related pathways/superpathways are miRNAs involved in DNA damage response and Cell differentiation - expanded index. The drugs Cisplatin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include tongue, lymph node and tonsil.

Sources

Related Diseases for Tongue Squamous Cell Carcinoma

Diseases related to Tongue Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 183)

#	Related Disease	Score	Top Affiliating Genes
1	tongue carcinoma	32.2	MIR21 MIR139 MALAT1
2	oral squamous cell carcinoma	31.9	UCA1 MIR486-1 MIR21 MIR145 MIR139 MIR133B
3	squamous cell carcinoma, head and neck	31.7	MIR486-1 MIR222 MIR21 MIR145 MIR139 CYTOR
4	head and neck cancer	31.6	MIR486-1 MIR222 MIR21 MIR145 MIR139
5	oral cavity cancer	31.2	MIR486-1 MIR21 MIR145 MIR139
6	oropharynx cancer	31.1	MIR486-1 MIR21 MIR139
7	thyroid cancer, nonmedullary, 1	31.0	MIR222 MEG3 MALAT1 HOTTIP
8	thyroid carcinoma	31.0	UCA1 MALAT1 AFAP1-AS1
9	lung cancer susceptibility 3	30.9	MIR486-1 MIR21 MIR145 MIR139 MEG3 MALAT1
10	nasopharyngeal carcinoma	30.7	NKILA MIR486-1 MIR21 MIR145 MEG3 MALAT1
11	kidney cancer	30.7	MIR21 MIR145 MEG3 MALAT1
12	osteogenic sarcoma	30.7	UCA1 MEG3 MALAT1 HOTTIP
13	esophageal cancer	30.7	UCA1 MIR486-1 MIR222 MIR21 MIR145 MIR139
14	myocardial infarction	30.6	MIR486-1 MIR21 MIR145 MIR139 MIR133B BRINP3
15	gastric cancer	30.6	UCA1 MIR486-1 MIR222 MIR21 MIR145 MIR139
16	hepatocellular carcinoma	30.5	UCA1 PCBP2-OT1 NKILA MIR486-1 MIR222 MIR21
17	squamous cell carcinoma	11.5
18	lip and oral cavity cancer	10.9
19	down syndrome	10.6
20	esophagus adenocarcinoma	10.5	MIR21 MIR145 AFAP1-AS1
21	tongue disease	10.5	UCA1 MIR486-1 MIR21 MIR145 MIR139
22	biliary tract cancer	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
23	esophageal disease	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
24	bladder disease	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
25	gallbladder disease	10.5	MIR486-1 MIR222 MIR145 CYTOR
26	lymphatic system cancer	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
27	lymphatic system disease	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
28	colonic disease	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
29	central nervous system cancer	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
30	uterine anomalies	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
31	connective tissue cancer	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
32	laryngeal disease	10.5	MIR486-1 MIR21 MIR145 MIR139
33	esophagus squamous cell carcinoma	10.5	NKILA MEG3 MALAT1 HOTTIP CYTOR AFAP1-AS1
34	pancreas disease	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
35	spinal disease	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
36	ovary epithelial cancer	10.5	MIR222 MIR21 MIR145 MIR139
37	bone cancer	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
38	male reproductive organ cancer	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
39	glioma	10.5	UCA1 MIR222 MIR21 MEG3 MALAT1 HOTTIP
40	immune system disease	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
41	cholangiocarcinoma	10.5	UCA1 MIR21 MALAT1 AFAP1-AS1
42	male reproductive system disease	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
43	bile duct adenocarcinoma	10.5	MIR486-1 MIR21 MIR145 MIR139
44	reproductive system disease	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
45	high grade glioma	10.5	MIR21 MIR145 MEG3 MALAT1 HOTTIP CYTOR
46	urinary system disease	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
47	female reproductive system disease	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
48	bile duct disease	10.5	MIR486-1 MIR21 MIR145 MIR139
49	large intestine cancer	10.5	MIR486-1 MIR222 MIR21 MIR145 MIR139
50	biliary tract disease	10.5	MIR486-1 MIR21 MIR145 MIR139

Graphical network of the top 20 diseases related to Tongue Squamous Cell Carcinoma:

Sources

Symptoms & Phenotypes for Tongue Squamous Cell Carcinoma

Sources

Drugs & Therapeutics for Tongue Squamous Cell Carcinoma

Drugs for Tongue Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 26)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

2

Fluorouracil

Approved

Phase 2

51-21-8

3385

3

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

4

Nivolumab

Approved

Phase 2

946414-94-4

5

Ipilimumab

Approved

Phase 2

477202-00-9

6

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Synonyms:

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside

(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

14-Hydroxydaunomycin

14-Hydroxydaunorubicine

ADM

ADR

Adriablastin

Adriablastine

Adriamycin

Adriamycin PFS

Adriamycin RDF

Adriamycin Semiquinone

Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride

Adriblastin

Adriblastina

Adriblastine

Adrimedac

Baxter brand OF doxorubicin hydrochloride

Bedford brand OF doxorubicin hydrochloride

Bristol-myers squibb brand OF doxorubicin hydrochloride

Caelyx

Cell pharm brand OF doxorubicin hydrochloride

Columbia brand OF doxorubicin hydrochloride

DM2

DOXIL

Doxo

Doxo cell

Doxo-cell

Doxolem

DOXORUBICIN

Doxorubicin HCl

Doxorubicin hexal

Doxorubicin hydrochloride

Doxorubicin NC

Doxorubicina

Doxorubicina [INN-Spanish]

Doxorubicina ferrer farm

Doxorubicina funk

Doxorubicina tedec

Doxorubicine

Doxorubicine [INN-French]

Doxorubicine baxter

Doxorubicinum

Doxorubicinum [INN-Latin]

Doxotec

Elan brand OF doxorubicin hydrochloride

Farmiblastina

Ferrer brand OF doxorubicin hydrochloride

Hexal brand OF doxorubicin hydrochloride

Hydrochloride, doxorubicin

HYDROXYDAUNORUBICIN

Kenfarma brand OF doxorubicin hydrochloride

Lemery brand OF doxorubicin hydrochloride

Medac brand OF doxorubicin hydrochloride

Myocet

Neocorp brand OF doxorubicin hydrochloride

NSC-123127

Onkodox

Onkoworks brand OF doxorubicin hydrochloride

Pfizer brand OF doxorubicin hydrochloride

Prasfarma brand OF doxorubicin hydrochloride

RDF Rubex

Resmycin

Ribodoxo

Ribosepharm brand OF doxorubicin hydrochloride

Rubex

Tedec meiji brand OF doxorubicin hydrochloride

Urokit doxo cell

Urokit doxo-cell

VALRUBICIN IMPURITY, DOXORUBICIN

7

Quercetin

Experimental, Investigational

Phase 2

117-39-5

10283929 5320834 5280343

Synonyms:

(2S,3R,4R,5R)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl (2S,3S,4S,5R,6S)-6-{[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one

2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-benzopyran-4-one

2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one

2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-1-benzopyran-3-yl b-D-glucopyranosyl-(1->6)-b-D-glucopyranoside

2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-1-benzopyran-3-yl b-D-glucosyl-(1->6)-b-D-glucoside

2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-1-benzopyran-3-yl beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranoside

2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-1-benzopyran-3-yl beta-D-glucosyl-(1->6)-beta-D-glucoside

2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-1-benzopyran-3-yl β-D-glucopyranosyl-(1->6)-β-D-glucopyranoside

2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-1-benzopyran-3-yl β-D-glucosyl-(1->6)-β-D-glucoside

3,3',4,5,7-Pentahydroxyflavone

3,3',4',5,7-Pentahydroxyflavone

3,3’,4’,5,7-Pentahydroxyflavone

3,4',5,5',7-Pentahydroxy-flavone

3',4',5,7-Tetrahydroxyflavan-3-ol

3',4',5,7-Tetrahydroxyflavon-3-ol

3,5,7,3',4'-Pentahydroxyflavone

3,5,7,3’,4’-Pentahydroxyflavone

3,5,7-Trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-ON

3,5,7-Trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one

3’-Hydroxykaempferol

3'-Hydroxykaempferol

b-D-Glucosyl-(1->6)-b-D-glucoside

beta-D-Glucosyl-(1->6)-beta-D-glucoside

C.I. NATURAL RED 1

Dikvertin

Flavin meletin

LDN 0052529

LDN-0052529

Meletin

NSC 57655

NSC 9219

NSC-57655

NSC-9219

QUERCETIN

Quercetin 3-b-gentiobioside

Quercetin 3-gentiobioside

Quercetin 3-O-gentobioside

Quercetin 3-β-gentiobioside

Quercetin b-D-glucopyranosyl-(1->6)-b-D-glucopyranoside

Quercetin beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranoside

Quercetin dihydrate

Quercetin β-D-glucopyranosyl-(1->6)-β-D-glucopyranoside

Quercetin-3-gentiobioside

Quercetine

Quercetol

Quertin

Quertine

Sophoretin

Xanthaurine

Β-D-glucosyl-(1->6)-β-D-glucoside

8

Anesthetics

Phase 2

9

Antimitotic Agents

Phase 2

10

Tubulin Modulators

Phase 2

11

Immunoglobulins

Phase 2

12

Immune Checkpoint Inhibitors

Phase 2

13

Antibodies, Monoclonal

Phase 2

14

Antibodies

Phase 2

15

Antineoplastic Agents, Immunological

Phase 2

16

Anti-Bacterial Agents

Phase 2

17

Antibiotics, Antitubercular

Phase 2

18

Liposomal doxorubicin

Phase 2

19

Antioxidants

Phase 2

20

Protective Agents

Phase 2

21

Ribavirin

Approved

36791-04-5

37542

22

Luteolin

Experimental

Early Phase 1

491-70-3

5280445

23

Hemostatics

24

Antiviral Agents

25

Anti-Infective Agents

26

Antimetabolites

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer	Recruiting	NCT04333537	Phase 2, Phase 3	Imaging Agent
2	Role of Neo-adjuvant Chemotherapy in Organ Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue	Unknown status	NCT02985255	Phase 2	Docetaxel;Cisplatin;5FU
3	Phase 2 Study (With Safety Lead in) of the Safety, Tolerability and Efficacy of Anti-CTLA4 (Ipilimumab) and Anti-PD-1 (Nivolumab) in Combination With Radiation Therapy to 50-66 Gy in Low-Intermediate Volume, Local-Regionally Advanced HPV-Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)	Recruiting	NCT03799445	Phase 2
4	Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line	Not yet recruiting	NCT05456022	Phase 2	Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one;Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT);Doxorubicin chemotherapeutic drug as a positive control
5	Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line: In Vitro Study	Unknown status	NCT03288298	Early Phase 1	luteolin;nano-luteolin
6	Oncological Outcome of Contralateral Submental Artery Island Flap Versus Primary Closure in Tongue Squamous Cell Carcinoma (Randomize Noninferiority Clinical Trial)	Unknown status	NCT03440151
7	A Pilot Study to Assess the Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma	Active, not recruiting	NCT01268579		ribavirin

Search NIH Clinical Center for Tongue Squamous Cell Carcinoma

Sources

Genetic Tests for Tongue Squamous Cell Carcinoma

Sources

Anatomical Context for Tongue Squamous Cell Carcinoma

Organs/tissues related to Tongue Squamous Cell Carcinoma:

FMA: Tongue

MalaCards : Tongue, Lymph Node, Tonsil, T Cells, Endothelial, Bone Marrow, Skeletal Muscle

Sources

Publications for Tongue Squamous Cell Carcinoma

Articles related to Tongue Squamous Cell Carcinoma:

(show top 50) (show all 1548)

#	Title	Authors	PMID	Year
1	MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. ⁶² ⁴⁶	Liu X...Zhou X	19487542	2009
2	MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. ⁴⁶	Li J...Song E	19509158	2009
3	Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. ⁴⁶	Wong TS...Ignace Wei W	18464261	2008
4	Genome-wide profiling of dysregulated piRNAs and their target genes implicated in oncogenicity of tongue squamous cell carcinoma. ⁶²	Chattopadhyay T...Mallick B	36179965	2023
5	Constitutive activation of activator protein-1 as a cellular switch and its innovative role in the development of molecular targets for tongue squamous cell carcinoma treatment. ⁶²	Saravanan M	36244258	2022
6	Facial-submental island flap for reconstruction of hemitongue defects in young, middle-aged and elderly patients with early and middle stage oral tongue squamous cell carcinoma. ⁶²	Wang Y...Chen R	36471377	2022
7	Tumor-stroma ratio can predict lymph-node metastasis in cT1/2N0 oral tongue squamous cell carcinoma independent of tumor budding grade. ⁶²	Sakai T...Yamasoba T	36197545	2022
8	miRNome-transcriptome analysis unveils the key regulatory pathways involved in the tumorigenesis of tongue squamous cell carcinoma. ⁶²	Gupta P...Mallick B	36255066	2022
9	Overexpression of circFNDC3B promotes the progression of oral tongue squamous cell carcinoma through the miR-1322/MED1 axis. ⁶²	Chen X...Liang J	35916453	2022
10	Involvement of AMPKα and MAPK-ERK/-JNK Signals in Docetaxel-Induced Human Tongue Squamous Cell Carcinoma Cell Apoptosis. ⁶²	Su CC...Chen YW	36430348	2022
11	Activated fibroblasts induce immune escape of TSCC through CCL25/AKT pathway. ⁶²	Li Y...He Y	36437627	2022
12	Development and validation of novel nomograms to predict survival of patients with tongue squamous cell carcinoma. ⁶²	Luo XY...Zhu HY	36405263	2022
13	Early-Stage Oral Tongue Squamous Cell Carcinoma and a Positive Sentinel Lymph Node Biopsy: Description of a Prognostic Correlation between Pre-Treatment Inflammatory Biomarkers, the Depth of Invasion and the Worst Pattern of Invasion. ⁶²	Salzano G...Ionna F	36422107	2022
14	High-Frequency Intraoral Ultrasound for Preoperative Assessment of Depth of Invasion for Early Tongue Squamous Cell Carcinoma: Radiological-Pathological Correlations. ⁶²	Caprioli S...Cittadini G	36429617	2022
15	Genome-wide DNA methylation profiling in tongue squamous cell carcinoma. ⁶²	Rapado-Gonzalez O...Suarez-Cunqueiro MM	36398465	2022
16	The role of magnetic resonance imaging in assessing the extent of tongue squamous cell carcinoma: A prospective cohort study. ⁶²	Zhang YY...Han ZX	35257931	2022
17	Role of dysregulated miRNAs profiles as hallmarks in the pathogenesis and differential regulation of tongue squamous cell carcinoma. ⁶²	Yasasve M...Saravanan M	36081305	2022
18	HSP90B1 overexpression is associated with poor prognosis in tongue squamous cell carcinoma. ⁶²	Chen YB...Chen S	35580785	2022
19	MAP3K11 facilitates autophagy activity and is correlated with malignancy of oral squamous cell carcinoma. ⁶²	Liu PF...Shu CW	36103355	2022
20	Modified submandibular mandibulotomy approach without lip-splitting in tongue cancer. ⁶²	Wang Y...Chen W	36104264	2022
21	G-Quadruplex Aptamer-Ligand Characterization. ⁶²	Moreira D...Cruz C	36296374	2022
22	Tertiary lymphoid structures associate with improved survival in early oral tongue cancer. ⁶²	Almangush A...Leivo I	36309667	2022
23	Correction to: Elective Neck Dissection Versus Observation in cT1-T2 Oral Tongue Squamous Cell Carcinoma: A Meta-Analysis of 11,973 Patients. ⁶²	Akheel M...Wadhwania A	36454204	2022
24	[High expression of CCBE1 in adjacent tissues of tongue squamous cell carcinoma is correlated with pericancerous lymphatic vessel proliferation and poor 5-year survival outcomes]. ⁶²	Zhong J...Chen W	36329590	2022
25	Hsa_circ_0081069 facilitates tongue squamous cell carcinoma progression by modulating MAP2K4 expression via miR-634. ⁶²	Pan C...Xiao H	36181561	2022
26	Elective Neck Dissection Versus Observation in cT1-T2 Oral Tongue Squamous Cell Carcinoma: A Meta-Analysis of 11,973 Patients. ⁶²	Akheel M...Wadhwania A	36452646	2022
27	Qilan preparation inhibits proliferation and induces apoptosis by down-regulating microRNA-21 in human Tca8113 tongue squamous cell carcinoma cells. ⁶²	Jiamin D...Lin Z	36083475	2022
28	The incidence of occult level IV nodal metastasis in tongue squamous cell carcinoma: a 20 year review. ⁶²	Wu J...Ebrahim AK	36196806	2022
29	TWIST1 regulates proliferation, migration, and invasion and is a prognostic marker for oral tongue squamous cell carcinoma. ⁶²	de Morais EF...de Almeida Freitas R	36285599	2022
30	Prognosis of tongue squamous cell carcinoma associated with individual surgical margin and pathological features. ⁶²	Cho S...Kim SM	36316182	2022
31	[Retracted] Long non‑coding RNA PRNCR1 exerts oncogenic effects in tongue squamous cell carcinoma in vitro and in vivo by sponging microRNA‑944 and thereby increasing HOXB5 expression. ⁶²	Lin C...Liu D	36004464	2022
32	[hsa_circ_0000231 affects the progression of tongue squamous cell carcinoma by activating Wnt/β-catenin signaling pathway]. ⁶²	Chen QW...Wu H	36319130	2022
33	Radiation modulates expression and related activities of c-Met protein in oral tongue squamous cell carcinoma cell lines. ⁶²	Al-Jamaei AAH...Helder MN	36053327	2022
34	Corrigendum to <[Photodiagnosis and Photodynamic Therapy, Volume 32, December 2020, 102048]>. ⁶²	Ding J...Sun G	36068732	2022
35	Protocol for a multicentre, prospective observational study of elective neck dissection for clinically node-negative oral tongue squamous cell carcinoma (END-TC study). ⁶²	Yanamoto S...Kirita T	36100307	2022
36	Establishment and characterization of novel autologous pair cell lines from two Indian non‑habitual tongue carcinoma patients. ⁶²	Dwivedi N...Das M	35796014	2022
37	Immunoexpression of REGγ and apoptosis-related proteins in oral tongue squamous cell carcinoma. ⁶²	Brasileiro Junior VL...Souza LB	34955353	2022
38	Tongue squamous cell carcinoma resists hyperthermia treatment by promoting Id-1 expression mediated EMT. ⁶²	Luo D...Zhou R	35788271	2022
39	lncKRT16P6 promotes tongue squamous cell carcinoma progression by sponging miR‑3180 and regulating GATAD2A expression. ⁶²	Zhang M...Chen J	35904180	2022
40	Prognostic Value of Lymph Node Density Compared to Pre-operative Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio in Patients with Tongue Squamous Cell Carcinoma. ⁶²	Khazravi M...Jalaeefar A	36274869	2022
41	MiR-873-5p modulates progression of tongue squamous cell carcinoma via targeting SEC11A. ⁶²	Yao Y...Mu JW	33675129	2022
42	LINC00460 facilitated tongue squamous cell carcinoma progression via the miR-320b/IGF2BP3 axis. ⁶²	Wu K...Xu X	33660359	2022
43	Adequacy of Disease Control by Supraomohyoid Neck Dissection in cT1/T2 Tongue Cancer. ⁶²	Iandelli A...Huang SF	36143322	2022
44	Use of the double-paddle anterolateral thigh flap for locally advanced tongue carcinoma requiring second site reconstruction. ⁶²	Nguyen KA...Wein RO	36055115	2022
45	Recovery pattern analysis of swallowing function in patients undergoing total glossectomy and hemiglossectomy. ⁶²	Deng W...Liao G	35752136	2022
46	Stabilization of a DNA aptamer by ligand binding. ⁶²	Santos T...Cruz C	35550917	2022
47	Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). ⁶²	Michikawa C...Silver N	35834946	2022
48	Treatment outcomes and prognostic factors in oral tongue cancer: a 20-year retrospective study at the National Cancer Center, South Korea. ⁶²	Kim MG...Choi SW	36043249	2022
49	Depth of Invasion as an Independent Predictor of Survival in Patients of Stage III Squamous Cell Carcinoma of the Oral Tongue. ⁶²	Tandon S...Gairola M	34918353	2022
50	Utility of a palatal speech appliance combined with the five-point eight-line segment technique in total tongue reconstruction. ⁶²	Han SW...Han W	35086759	2022

Sources

Genes for Tongue Squamous Cell Carcinoma

Genes related to Tongue Squamous Cell Carcinoma (3 elite genes):

(show top 50) (show all 79)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MIR222	MicroRNA 222	RNA Gene	362.91	Causal ⁴⁶ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	19487542
2	MIR21	MicroRNA 21	RNA Gene	356.03	Causal ⁴⁶ DISEASES inferred ¹⁴	19509158
3	MIR133B	MicroRNA 133b	RNA Gene	354.64	Causal ⁴⁶ DISEASES inferred ¹⁴	18464261
4	UCA1	Urothelial Cancer Associated 1	RNA Gene	156.33	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	24332332 24817925
5	LINC00673	Long Intergenic Non-Protein Coding RNA 673	RNA Gene	155.94	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	28039470
6	HOTTIP	HOXA Distal Transcript Antisense RNA	RNA Gene	155.84	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26058875
7	AFAP1-AS1	AFAP1 Antisense RNA 1	RNA Gene	155.76	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	29310682
8	CYTOR	Cytoskeleton Regulator RNA	RNA Gene	155.73	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28367232
9	PCBP2-OT1	PCBP2 Overlapping Transcript 1	RNA Gene	154.76	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	27637778
10	LINC01527	Long Intergenic Non-Protein Coding RNA 1527	RNA Gene	154.68	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25045670
11	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	153.97	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	27353727 27586393
12	LINC01503	Long Intergenic Non-Protein Coding RNA 1503	RNA Gene	153.7	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25045670
13	MEG3	Maternally Expressed 3	RNA Gene	153.38	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	24343426 26885901
14	NKILA	NF-KappaB Interacting LncRNA	RNA Gene	150	Experimental evidence: Regulation ³⁷	27613832
15	STXBP5	Syntaxin Binding Protein 5	Protein Coding	150	Experimental evidence: Regulation ³⁷	25045670
16	DND1	DND MicroRNA-Mediated Repression Inhibitor 1	Protein Coding	22.73	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
17	BRINP3	BMP/Retinoic Acid Inducible Neural Specific 3	Protein Coding	20.53	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Expressions (show sections)
18	MIR486-1	MicroRNA 486-1	RNA Gene	9.51	DISEASES inferred ¹⁴ ¹⁴
19	MIR145	MicroRNA 145	RNA Gene	9.03	DISEASES inferred ¹⁴ ¹⁴
20	MIR139	MicroRNA 139	RNA Gene	8.94	DISEASES inferred ¹⁴ ¹⁴
21	MIR195	MicroRNA 195	RNA Gene	8.89	DISEASES inferred ¹⁴ ¹⁴
22	MIR196A1	MicroRNA 196a-1	RNA Gene	8.7	DISEASES inferred ¹⁴ ¹⁴
23	MIR483	MicroRNA 483	RNA Gene	8.68	DISEASES inferred ¹⁴ ¹⁴
24	MIR33A	MicroRNA 33a	RNA Gene	8.65	DISEASES inferred ¹⁴ ¹⁴
25	MIR204	MicroRNA 204	RNA Gene	8.56	DISEASES inferred ¹⁴ ¹⁴
26	MIR15A	MicroRNA 15a	RNA Gene	8.52	DISEASES inferred ¹⁴ ¹⁴
27	MIR423	MicroRNA 423	RNA Gene	8.52	DISEASES inferred ¹⁴ ¹⁴
28	MIR17	MicroRNA 17	RNA Gene	8.52	DISEASES inferred ¹⁴ ¹⁴
29	MIR30A	MicroRNA 30a	RNA Gene	8.43	DISEASES inferred ¹⁴ ¹⁴
30	MIR199A1	MicroRNA 199a-1	RNA Gene	8.42	DISEASES inferred ¹⁴ ¹⁴
31	MIR142	MicroRNA 142	RNA Gene	8.37	DISEASES inferred ¹⁴ ¹⁴
32	MIR99A	MicroRNA 99a	RNA Gene	8.35	DISEASES inferred ¹⁴ ¹⁴
33	MIR143	MicroRNA 143	RNA Gene	8.24	DISEASES inferred ¹⁴ ¹⁴
34	MIRLET7A1	MicroRNA Let-7a-1	RNA Gene	8.2	DISEASES inferred ¹⁴ ¹⁴
35	MIR185	MicroRNA 185	RNA Gene	8.17	DISEASES inferred ¹⁴ ¹⁴
36	MIR503	MicroRNA 503	RNA Gene	8.14	DISEASES inferred ¹⁴ ¹⁴
37	MIR149	MicroRNA 149	RNA Gene	8.09	DISEASES inferred ¹⁴ ¹⁴
38	MIR181A1	MicroRNA 181a-1	RNA Gene	8.07	DISEASES inferred ¹⁴ ¹⁴
39	MIR939	MicroRNA 939	RNA Gene	8.03	DISEASES inferred ¹⁴ ¹⁴
40	MIR485	MicroRNA 485	RNA Gene	7.83	DISEASES inferred ¹⁴ ¹⁴
41	MIR409	MicroRNA 409	RNA Gene	7.55	DISEASES inferred ¹⁴ ¹⁴
42	MIR590	MicroRNA 590	RNA Gene	7.52	DISEASES inferred ¹⁴ ¹⁴
43	MIR125A	MicroRNA 125a	RNA Gene	7.51	DISEASES inferred ¹⁴ ¹⁴
44	MIR210	MicroRNA 210	RNA Gene	7.48	DISEASES inferred ¹⁴ ¹⁴
45	MIR150	MicroRNA 150	RNA Gene	7.45	DISEASES inferred ¹⁴ ¹⁴
46	MIR302B	MicroRNA 302b	RNA Gene	7.4	DISEASES inferred ¹⁴ ¹⁴
47	MIR455	MicroRNA 455	RNA Gene	7.39	DISEASES inferred ¹⁴ ¹⁴
48	MIR144	MicroRNA 144	RNA Gene	7.32	DISEASES inferred ¹⁴ ¹⁴
49	MIR193A	MicroRNA 193a	RNA Gene	7.3	DISEASES inferred ¹⁴ ¹⁴
50	MIR28	MicroRNA 28	RNA Gene	7.28	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Tongue Squamous Cell Carcinoma

Sources

Expression for Tongue Squamous Cell Carcinoma

Genes differentially expressed in tissues of Tongue Squamous Cell Carcinoma patients vs. healthy controls: ³⁵ (show all 30)

#	Gene	Description	Tissue	Up/Dn	Fold Change (log2)	P value
1	MMP1	matrix metallopeptidase 1	Oral Cavity	+	6.95	0.000
2	TMPRSS11B	transmembrane serine protease 11B	Oral Cavity	-	5.73	0.000
3	MAL	mal, T cell differentiation protein	Oral Cavity	-	5.07	0.000
4	CRNN	cornulin	Oral Cavity	-	4.97	0.000
5	KRT13	keratin 13	Oral Cavity	-	4.67	0.001
6	MYH2	myosin heavy chain 2	Oral Cavity	-	4.12	0.005
7	PTHLH	parathyroid hormone like hormone	Oral Cavity	+	4.09	0.000
8	KRT17	keratin 17	Oral Cavity	+	3.76	0.000
9	CXCL12	C-X-C motif chemokine ligand 12	Oral Cavity	-	3.73	0.000
10	LAMC2	laminin subunit gamma 2	Oral Cavity	+	3.68	0.000
11	CLCA4	chloride channel accessory 4	Oral Cavity	-	3.65	0.000
12	CXCL1	C-X-C motif chemokine ligand 1	Oral Cavity	+	3.44	0.000
13	LDB3	LIM domain binding 3	Oral Cavity	-	3.41	0.003
14	MMP3	matrix metallopeptidase 3	Oral Cavity	+	3.39	0.000
15	CLU	clusterin	Oral Cavity	-	3.38	0.000
16	CFAP251	cilia and flagella associated protein 251	Oral Cavity	+	3.37	0.000
17	GALNT16	polypeptide N-acetylgalactosaminyltransferase 16	Oral Cavity	-	3.36	0.000
18	PRR9	proline rich 9	Oral Cavity	+	3.34	0.004
19	CXCL8	C-X-C motif chemokine ligand 8	Oral Cavity	+	3.33	0.000
20	CRISP3	cysteine rich secretory protein 3	Oral Cavity	-	3.23	0.010
21	CYP4B1	cytochrome P450 family 4 subfamily B member 1	Oral Cavity	-	3.21	0.000
22	SPINK5	serine peptidase inhibitor Kazal type 5	Oral Cavity	-	3.20	0.002
23	S100A7A	S100 calcium binding protein A7A	Oral Cavity	+	3.15	0.001
24	IFI6	interferon alpha inducible protein 6	Oral Cavity	+	3.13	0.000
25	INHBA	inhibin subunit beta A	Oral Cavity	+	3.13	0.001
26	KRT4	keratin 4	Oral Cavity	-	3.11	0.000
27	ABCA8	ATP binding cassette subfamily A member 8	Oral Cavity	-	3.10	0.000
28	FAM3B	FAM3 metabolism regulating signaling molecule B	Oral Cavity	-	3.08	0.007
29	EPPK1	epiplakin 1	Oral Cavity	+	3.07	0.000
30	SPRR3	small proline rich protein 3	Oral Cavity	-	3.06	0.025

Search GEO for disease gene expression data for Tongue Squamous Cell Carcinoma.

Sources

Pathways for Tongue Squamous Cell Carcinoma

Pathways related to Tongue Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	miRNAs involved in DNA damage response ⁷⁴	10.96	MIR222 MIR21 MIR145
2	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	10.82	MIR486-1 MIR222 MIR145 MIR133B
3	ncRNAs involved in STAT3 signaling in hepatocellular carcinoma ⁷⁴	10.41	UCA1 MIR21

Sources

GO Terms for Tongue Squamous Cell Carcinoma

Cellular components related to Tongue Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.47	MIR486-1 MIR222 MIR21 MIR145 MIR139 MIR133B

Biological processes related to Tongue Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	miRNA-mediated gene silencing	GO:0035195	10	MIR486-1 MIR222 MIR21 MIR145 MIR139 MIR133B
2	negative regulation of interleukin-21 production	GO:0032705	9.16	MIR222 MIR21
3	positive regulation of cellular response to hypoxia	GO:1900039	8.96	MIR21 MIR145
4	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	8.92	MIR222 MIR21 MIR145 MIR133B

Molecular functions related to Tongue Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.5	MIR486-1 MIR21 MIR145 MIR139 MIR133B DND1
2	mRNA base-pairing translational repressor activity	GO:1903231	9.1	MIR486-1 MIR222 MIR21 MIR145 MIR139 MIR133B

Sources

Sources for Tongue Squamous Cell Carcinoma

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

MCID: TNG009 MIFTS: 45	Tongue Squamous Cell Carcinoma Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Smell/Taste diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables